In the (second) Vertex book they spent a good deal talking about that (I vaguely recall the incident) where the street got all worried about what turned out to be an error and under reporting of Incivek numbers. They talked about vertex trying to get (I believe it was IMS) to issue a PR about it too.
ABBV’s Viekira-Pak scripts will be underreported by IMS
Why would the manufacturer and the supplier demand that sales be obscured, or hidden? It must be a short term tactical reason, for eventually the numbers will out.
Regarding Scripts. I'm sure it's too early to even think of Abbvie's scripts but your premise has always been that the market was constrained by the provider side. Do you know if Gilead has seen a decline?
News 
Market Data 
Discover 
